JPRN-UMIN000000758已完成3 期
Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs - Phase III clinical trial for AT-877 (i.v.) in acute ischemic stroke
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 770
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients having a history of coronary, renal, hepatic or metabolic disease. Patients exhibiting dysemia (2) Other conditons at the discretion of the investigator
研究者
相似试验
未知
2 期
Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensioPulmonary arterial hypertensionJPRN-jRCT2080220801ASAHI KASEI PHARMA CORPORATIO
未知
3 期
Phase III clinical study of AFT-801 (confirmatory study) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220352Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
进行中（未招募）
3 期
AL8326 in advanced Small Cell Lung CancerSmall Cell Lung CancerCancerISRCTN79004846Advenchen Pharmaceuticals, LLC243
已完成
3 期
Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosisAcute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)JPRN-jRCT2080223271ASAHI KASEI PHARMA CORPORATIO74
未知
3 期
Phase 3 clinical study of AFT-801(confirmatory study 0305) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220749Mitsubishi Tanabe Pharma Alfresa Pharma Corporation